On site payment Meet with… National Cancer Institute
JLABS , 3210 Merryfield Row , San Diego , CA 92121
August 20, 2015 from 15:00 PM to 18:00 PM (PDT)
$10 - $35
Twice as many people survived cancer in 2012 than did in 1992. Today, the National Cancer Institute (NCI) is poised to further accelerate the rate of scientific discovery and reduce the burden of cancer in the United States and around the world.
The NCI continues to develop new funding opportunities that adapt to changes in the way that science is conducted. Supporting the best scientists is paramount. The Federal Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs are a critical source of non-dilutive financing for early stage companies, providing over $110M in fiscal year 2014 to develop next generation technologies.
Program Directors Patti Weber and Jonathan Franca-Koh will cover:
- NIH/NCI SBIR Overview and Initiatives, as well as eligibility requirements.
- NIH SBIR/STTR process and new cancer-focused grant funding opportunities from NCI.
- New NCI SBIR/STTR initiatives such as NIH Innovation Corps (I-Corps™) Team Training Pilot Program.
- NCI efforts to help NCI SBIR-funded companies to connect with investors, venture capitalists, strategic partners, and business leaders from the biotech and pharmaceutical industries.
- Practical strategies on how to successfully submit competitive research proposals.
Following the presentations and Q&A, attendees will have the opportunity to meet one-on-one with NCI SBIR leaders to further discuss their companies and projects. If you are interested, please send an executive summary to [email protected] and [email protected] by Wednesday, August 12.
9:00 AM | Registration Opens, Breakfast
9:30 AM | Presentation & Q&A
11:15 AM | One-on-one Meetings*
3:00 PM | Program Close
*Companies must have applied for a one-on-one meeting ahead of time and be approved. If you are interested, please send an executive summary to [email protected] and [email protected] by Wednesday, August 12.
National Cancer Institute Participating Representatives:
Jonathan Franca-Koh | Program Director - SBIR Development Center, National Cancer Institute read bio»
Patti Weber | Program Director - SBIR Development Center, National Cancer Institute read bio»
About National Cancer Institute:
The National Cancer Institute (NCI) is part of the National Institutes of Health (NIH), which is one of 11 agencies that compose the Department of Health and Human Services (HHS). The NCI, established under the National Cancer Institute Act of 1937, is the Federal Government's principal agency for cancer research and training. The National Cancer Act of 1971 broadened the scope and responsibilities of the NCI and created the National Cancer Program. Over the years, legislative amendments have maintained the NCI authorities and responsibilities and added new information dissemination mandates as well as a requirement to assess the incorporation of state-of-the-art cancer treatments into clinical practice. The National Cancer Institute coordinates the National Cancer Program, which conducts and supports research, training, health information dissemination, and other programs with respect to the cause, diagnosis, prevention, and treatment of cancer, rehabilitation from cancer, and the continuing care of cancer patients and the families of cancer patients.
Read more about NCI»
Connect with NCI:
Presentation & Lunch
$25 | General Public
$35 | General Public - At the door
Includes presentation, Q&A, and breakfast. All attendees must pay this fee, regardless of one-on-one meeting status. Registration to attend the presentation, Q&A, and breakfast will remain open until August 19 (or full).
FREE | Application
FREE | Accepted Companies
Companies must have applied for a one-on-one meeting ahead of time and be approved. If you are interested, please send an executive summary to [email protected] and [email protected] by Wednesday, August 12. Your application will be reviewed and you will be notified of acceptance by email. Acceptance of a one-on-one meeting is not guaranteed as all applications must be approved.
3210 Merryfield Row
San Diego, CA
In Partnership with:
National Cancer Institute Representatives' Biographies:
Jonathan Franca-Koh, Ph.D. | Program Director - SBIR Development Center, National Cancer Institute
Dr. Jonathan Franca-Koh is a Program Director at the National Cancer Institute's Small Business Innovation Research (SBIR) Development Center. Jonathan manages SBIR & STTR grants and contracts with a focus on cancer therapeutics and novel tools for research and drug discovery. He provides oversight throughout the award period and mentors applicants and awardees in developing their technology goals and commercialization strategy. Additionally, he plays an active role in several center initiatives, including recent investor forums, workshops, targeted funding opportunities, and represents the NCI on the trans-NIH REACH program. Prior to joining the SBIR Development Center, Jonathan was a Program Director at the NCI Division of Cancer Biology and Center for Strategic Scientific Initiatives, overseeing the Physical Sciences-Oncology Centers (PS-OC) program, a network of interdisciplinary centers that brought together physical scientists and cancer biologists. Jonathan received his Ph.D. in Cell and Molecular Biology from the University of London's Institute of Cancer Research in 2003, and completed post-doctoral research at Johns Hopkins University and the J. Craig Venter Institute. In 2014 he completed his MBA from Johns Hopkins University, focusing on finance and health care innovation.
Connect with Jonathan:
Patti Weber, DrPH | Program Director - SBIR Development Center, National Cancer Institute
Dr. Patricia Weber is a Program Director at the National Cancer Institute's Small Business Innovation Research (SBIR) Development Center. Dr Weber manages SBIR & STTR grants and contracts focused in the areas cancer prevention, digital health, and cancer therapeutics, including small molecule, immunotherapeutics, and biologics. In her role she provides oversight throughout the award period and mentors awardees in their technology goals and commercialization strategy. Dr Weber also plays an active role in a number of initiatives including the NCI Investor Forum, workshops and targeted funding initiatives. Prior to joining the SBIR Development Center she held various management level positions in research and development in both San Diego and Western Montana. She was Director of Microbiology and Immunology at a San Diego-based biotech company that focused on the discovery and development of peptide therapeutics. She then moved to western Montana where she was the Team Leader of Cardiovascular Pharmacology at Ribi ImmunoChem Research (currently GSK) in Hamilton, MT. In addition to managing the preclinical development efforts of an intravenous biological product for the prevention of ischemia/reperfusion injury associated with cardiopulmonary bypass procedures, she also worked on licensing the therapeutic to potential pharmaceutical partners. She joined the International Heart Institute of Montana in 2000 where she managed the Tissue Engineering and Surgical Research Laboratories. Her work involved the preclinical development of cardiovascular devices including heart valves, bioengineered blood vessels and novel, stent-based devices. Dr. Weber completed her Masters and Doctorate in Public Health with an emphasis in Biomedical Sciences at the School of Public Health, University of California at Berkeley.
Connect with Patti:
About the Meet with... Series:
The purpose of the Meet with Series events sponsored by JLABS is to help start-up entrepreneurs, as well as the academic community, connect with potential partners, such as big pharma or other investment corporations, through one-on-one meetings. It is also a chance for the featured corporation to outline their specific business development goals and clarify what types of products or research they are interested in and how best to approach them to get the partnering process started. Past participants include the Wellcome Trust, Bill & Melinda Gates Foundation, MedImmune Ventures, NCI, Mercury Fund, DARPA's Biological Technologies Office, Correlation Ventures, Breakout Labs, New Enterprise Associates, Thomas McNerney & Partners, NCATS, Johnson & Johnson Innovation, Poliwogg, California Institute for Regenerative Medicine, Astellas Venture Management, and OrbiMed.